Covariates . | Risk of ESRD . | Mortality unrelated to ESRD* . | ||
---|---|---|---|---|
HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
Male sex | 1.37 (1.13, 1.68) | 0.002 | 1.23 (0.92, 1.63) | 0.17 |
Age (10-year increase) | 0.66 (0.59, 0.74) | <0.001 | 2.12 (1.84, 2.44) | <0.001 |
Baseline eGFR (10 mL/min increase) | 0.73 (0.70, 0.77) | <0.001 | 1.08 (1.02, 1.14) | 0.008 |
HbA1c (1% increase) | 1.22 (1.15, 1.29) | <0.001 | 1.10 (1.00, 1.21) | 0.059 |
Systolic blood pressure (10 mmHg increase) | 1.14 (1.08, 1.20) | <0.001 | 0.99 (0.92, 1.06) | 0.74 |
Current smoking | 1.21 (1.00, 1.47) | 0.048 | 1.78 (1.36, 2.33) | <0.001 |
Joslin vs. FinnDiane | 1.44 (1.14, 1.84) | 0.003 | 0.67 (0.44, 1.02)** | 0.063** |
Steno vs. FinnDiane | 0.54 (0.42, 0.69) | <0.001 | 1.01 (0.73, 1.41) | 0.94 |
INSERM vs. FinnDiane | 0.67 (0.49, 0.92) | 0.013 | 0.93 (0.61, 1.42) | 0.74 |
Covariates . | Risk of ESRD . | Mortality unrelated to ESRD* . | ||
---|---|---|---|---|
HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
Male sex | 1.37 (1.13, 1.68) | 0.002 | 1.23 (0.92, 1.63) | 0.17 |
Age (10-year increase) | 0.66 (0.59, 0.74) | <0.001 | 2.12 (1.84, 2.44) | <0.001 |
Baseline eGFR (10 mL/min increase) | 0.73 (0.70, 0.77) | <0.001 | 1.08 (1.02, 1.14) | 0.008 |
HbA1c (1% increase) | 1.22 (1.15, 1.29) | <0.001 | 1.10 (1.00, 1.21) | 0.059 |
Systolic blood pressure (10 mmHg increase) | 1.14 (1.08, 1.20) | <0.001 | 0.99 (0.92, 1.06) | 0.74 |
Current smoking | 1.21 (1.00, 1.47) | 0.048 | 1.78 (1.36, 2.33) | <0.001 |
Joslin vs. FinnDiane | 1.44 (1.14, 1.84) | 0.003 | 0.67 (0.44, 1.02)** | 0.063** |
Steno vs. FinnDiane | 0.54 (0.42, 0.69) | <0.001 | 1.01 (0.73, 1.41) | 0.94 |
INSERM vs. FinnDiane | 0.67 (0.49, 0.92) | 0.013 | 0.93 (0.61, 1.42) | 0.74 |
Adjusting for serum cholesterol and ACR in cohorts with available data had a small impact on the differences in ESRD risk or mortality unrelated to ESRD between cohorts and did not influence statistical inferences. Adjusting for age at type 1 diabetes diagnosis or diabetes duration instead of age did not change the statistical inferences on the differences between the cohorts.
*In Joslin, 69% of deaths were due to CVD. In FinnDiane, 55% of deaths were due to CVD. In Steno, 67% of deaths were due to CVD. In INSERM, causes of deaths were not available.
**In comparison with three other cohorts HR 0.68, P = 0.003.